May 15, 2020

Controlled Release Society Elects University of Pittsburgh’s Steven Little to Prestigious College of Fellows

The world’s leading organization for delivery science and technology has recognized University of Pittsburgh Professor and co-founder of Qrono Inc. Steven R. Little with election to its College of Fellows. 

May 04, 2020

Qrono Inc. to Present at Cooley’s 2020 National Capital Call Event

Qrono will present at Cooley LLP's 1st ever online national Digital Health & Life Sciences Capital Call. 6/4 11:30am-1:30pm.  This invitation-only event showcases Qrono and sixteen other life science and health companies.  Qrono will present its new antigen presenting cell-specific checkpoint inhibitor program.

June 05, 2018

Qrono completes NIH commercialization accelerator program

Qrono completed the 2017-2018 National Institutes of Health commercialization accelerator program.  Qrono refined its strategic developent plan with the help of industry and regulatory experts.

May 30, 2018

Steve Little wins recognition as Young Investigator of 2018

Qrono co-founder Prof. Steven Little was named Young Investigator of 2018 by Controlled Release Society.   This award acknowledges his advances in long acting formulation design and development, which have been commercialized by Qrono Inc.

December 05, 2017

Qrono wins innovation award.

The Pittsburgh Business Times has selected Qrono Inc. for its first annual Innovation Award based on the company’s potential to impact the healthcare industry.  This award recognizes Qrono for challenging conventional thinking with its new cancer therapies.

November 03, 2016

National Cancer Institute funds IND studies for QR206

The National Cancer Institute, part of the National Institutes of Health, has awarded Qrono Inc. a $1.5M small business innovation research contract to advance lead product candidate QR206 through Investigational New Drug studies.  

October 25, 2016

Qrono establishes proof-of-concept for lead product QR206

Working with University of Pittsburgh researchers, Qrono demonstrated safe and effective treatment of head and neck tumors with QR206 in established mouse model.  

Please reload